희소 세포 분리 시장 규모, 점유율, 동향 분석 리포트 : 제품 유형별, 세포 유형별, 기술별, 지역별, 부문별 예측(2024-2030년)

Rare Cell Isolation Market Growth & Trends:

The global rare cell isolation market size is anticipated to reach USD 3.46 billion by 2030, registering a CAGR of 9.71% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is attributed to the continuous technological advancements, increasing prevalence of chronic diseases, growing demand for personalized medicine, and advancements in cancer research. Furthermore, the isolation of rare stem cells is essential for regenerative medicine and stem cell therapy, thereby propelling the demand over the forecast period.

The COVID-19 pandemic has positively impacted the market by accelerating diagnostics and therapeutic research advancements. The urgent need to understand the virus and develop effective treatments has stimulated investment in cutting-edge cell isolation technologies, facilitating the rapid isolation and analysis of rare immune cells and circulating viral particles. Thus, the growing demand has driven innovation and collaboration across the biotech industry, resulting in enhanced single-cell analysis, liquid biopsy, and personalized medicine capabilities, boosting the demand for rare cell isolation over the forecast period.

The increasing prevalence of chronic diseases, especially cancer, has significantly increased the demand for rare cell isolation techniques. Isolation of these cells allows for early diagnosis, monitoring of treatment efficacy, and development of targeted therapies tailored to individual patients. By capturing and studying these rare cells, researchers and clinicians are anticipated to identify specific genetic mutations, recognize tumor behavior, and devise personalized treatment plans, ultimately improving patient outcomes and advancing the field of oncology. Thus, the growing demand for rare cells in predicting behavior is estimated to propel the market growth over the forecast period.

However, advanced rare cell isolation technologies, such as microfluidics and flow cytometry, often require significant investment. The high equipment, reagents, and maintenance costs can be prohibitive for many research institutions and clinical labs, limiting market expansion. In addition, the processes involved in rare cell isolation are technically complex, thus requiring specialized expertise and training. This complexity is anticipated to create a barrier to adoption, further hampering the market's growth.

Rare Cell Isolation Market Report Highlights:

• The reagent & kits segment dominated the market in 2023 and is expected to grow at the fastest CAGR from 2024 to 2030. The cost-effectiveness of reagents and kits compared to more sophisticated and expensive equipment for cell isolation plays a significant role in their widespread adoption
• The stem cell type segment held the largest share of 39.46% in 2023. The pharmaceutical and biotechnology industries rely heavily on isolated stem cells to screen for new drugs, study cellular responses, and assess the safety of potential treatments. This widespread application in research and industry underpins the segment dominance
• The microfluidics-based techniques technology segment dominated the market in 2023. Continuous innovation & advancements in microfluidics technology contributed to its leading position in the market. Researchers and companies are developing new microfluidic devices and methods that offer improved performance, ease of use, and integration with other analytical tools. These advancements are driving widespread adoption and expanding the applications of microfluidics-based cell isolation
• North America dominated the market in 2023 due to the growing cancer incidence, sedentary lifestyle, and rising prevalence of chronic diseases. On the other hand, Asia Pacific is anticipated to grow at the highest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Products Segment
  • 1.2.2. Cell Type Segment
  • 1.2.3. Technology Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
  • 1.8.1. Total Market: CAGR Calculation
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Rare cell isolation market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic and rare diseases
    • 3.2.1.2. Technological advancement and innovation in cell isolation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Strict regulations and compliances for cell separation
• 3.3. Rare Cell Isolation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Rare Cell Isolation Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Rare Cell Isolation Market Products Movement Analysis
• 4.3. Global Rare Cell Isolation Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagent & Kits
  • 4.4.1. Reagent & kits market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Instrument
  • 4.5.1. Instrument market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rare Cell Isolation Market: Cell Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Rare Cell Isolation Market Application Movement Analysis
• 5.3. Global Rare Cell Isolation Market Size & Trend Analysis, by cell type, 2018 to 2030 (USD Million)
• 5.4. Circulating Tumor Cells
  • 5.4.1. Circulating tumor cells market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Stem Cells
  • 5.5.1. Stem cells market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Fetal Cells
  • 5.6.1. Fetal cells market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Rare Immune Cells
  • 5.7.1. Rare immune cells market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Circulating Endothelial Cells
  • 5.8.1. Circulating endothelial cells market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Other Rare Cell Types
  • 5.9.1. Other rare cell types market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare cell isolation market: Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Rare Cell Isolation Market Technology Movement Analysis
• 6.3. Global Rare Cell Isolation Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 6.4. Microfluidics-based Techniques
  • 6.4.1. Microfluidics-based techniques market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Fluorescence-activated Cell Sorting
  • 6.5.1. Fluorescence-activated cell sorting market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Magnetic Bead Separation
  • 6.6.1. Magnetic bead separation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rare cell isolation market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. Miltenyi Biotec
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Thermo Fisher Scientific, Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Danaher
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. QIAGEN N.V.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Bio-techne
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. STEMCELL Technologies
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. CELLENION
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. RareCyte
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Illumina, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Bio-Rad Laboratories, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives